Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -19.62% is 57% above its 5-year average of -45.23%, near the high end of its 5-year range (-76.43%–-8.27%).
8.77% above its 12-month average of -21.51%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -8.27%.
NET PROFIT MARGIN
-19.62%
NET PROFIT MARGIN AVG TTM
-21.51%
NET PROFIT MARGIN AVG 3Y
-37.48%
NET PROFIT MARGIN AVG 5Y
-45.23%
NET PROFIT MARGIN AVG 10Y
-45.49%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+8.77%
CURRENT VS 3Y AVG
+47.65%
CURRENT VS 5Y AVG
+56.62%
CURRENT VS 10Y AVG
+56.87%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-7446.15%
vs the sector median at left
Neuronetics, Inc.
Market Cap
$155.14M
Net Profit Margin
-19.62%
TTM Avg
-21.51%
3Y Avg
-37.48%
5Y Avg
-45.23%
Market Cap
$154.79M
Net Profit Margin
-10.40%
TTM Avg
-6.28%
3Y Avg
-16.07%
5Y Avg
-47.85%
Market Cap
$152.82M
Net Profit Margin
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$157.72M
Net Profit Margin
-6.94%
TTM Avg
-8.61%
3Y Avg
-17.97%
5Y Avg
-12.59%
Market Cap
$159.14M
Net Profit Margin
-257.10%
TTM Avg
-196.56%
3Y Avg
-155.96%
5Y Avg
-114.00%
Market Cap
$150.43M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-6695.15%
Market Cap
$160.27M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.79%
Market Cap
$149.51M
Net Profit Margin
-39.55%
TTM Avg
-86.23%
3Y Avg
-76.35%
5Y Avg
-60.08%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuronetics, Inc. (STIM) | $155.14M | -19.62% | -21.51% | -37.48% | -45.23% |
| LifeMD, Inc. (LFMDP)vs › | $154.79M | -10.40% | -6.28% | -16.07% | -47.85% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | N/A | 0.00% | 0.00% | 0.00% |
| Inogen, Inc. (INGN)vs › | $157.72M | -6.94% | -8.61% | -17.97% | -12.59% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -257.10% | -196.56% | -155.96% | -114.00% |
| PepGen Inc. (PEPG)vs › | $159.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | 0.00% | 0.00% | 0.00% | -6695.15% |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.27M | 0.00% | 0.00% | 0.00% | 0.79% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -39.55% | -86.23% | -76.35% | -60.08% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.94M | -312.63% | -188.89% | -109.57% | -101.19% |
Operating Margin
-14.7%
Net Profit Margin
-19.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -8.27% |
| 2026-03-31 | -31.32% |
| 2025-12-31 | -17.13% |
| 2025-09-30 | -24.25% |
| 2025-06-30 | -26.56% |
| 2025-03-31 | -39.64% |
| 2024-12-31 | -56.29% |
| 2024-09-30 | -72.00% |
| 2024-06-30 | -59.77% |
| 2024-03-31 | -45.20% |
| 2023-12-31 | -26.47% |
| 2023-09-30 | -52.51% |
| 2023-06-30 | -27.83% |
| 2023-03-31 | -67.70% |
| 2022-12-31 | -45.55% |
| 2022-09-30 | -46.12% |
| 2022-06-30 | -63.83% |
| 2022-03-31 | -76.43% |
| 2021-12-31 | -50.83% |
| 2021-09-30 | -59.07% |
| 2021-06-30 | -52.98% |
| 2021-03-31 | -64.14% |
| 2020-12-31 | -23.47% |
| 2020-09-30 | -27.46% |
| 2020-06-30 | -79.71% |
| 2020-03-31 | -109.91% |
| 2019-12-31 | -43.52% |
| 2019-09-30 | -42.92% |
| 2019-06-30 | -42.81% |
| 2019-03-31 | -59.15% |
| 2018-12-31 | -39.29% |
| 2018-09-30 | -36.11% |
| 2018-06-30 | -56.57% |
| 2018-03-31 | -54.15% |
| 2017-12-31 | -40.67% |
| 2017-09-30 | -35.77% |
| 2017-06-30 | -27.82% |
| 2017-03-31 | -59.98% |
